Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells

Experimental and Molecular Pathology

Volumn 91, Issue 3, 2011, Pages 768-774

  Jiang, Ying ^a,b   Huang, Yeqing ^b   Cheng, Chun ^b   Lu, Weiqi ^a   Zhang, Yixin ^b   Liu, Xiaojuan ^b   Zou, Lin ^b   Ben, Qiwen ^c   Shen, Aiguo ^b  

^a FUDAN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Demethylation; Hydralazine; PPAR ; Proliferation; Thiazolidinedione; TNBC

Indexed keywords

CASPASE 3; HYDRALAZINE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; FLOW CYTOMETRY; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; PROMOTER REGION; WESTERN BLOTTING;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDRALAZINE; LIGANDS; MOLECULAR TARGETED THERAPY; PPAR GAMMA; RECEPTOR, ERBB-2; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 80054072725     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.09.007     Document Type: Article

References (34)

1. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Human Molecular Genetics 2001, 10:687-692.
2. Blanca S.P., Catalina T.B., Enrique P.C., Lucia T.C., Ignacio M. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clinical Cancer Research 2003, 9:1596-1603.
3. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research 2007, 13:2329-2334.
4. Carmelo B., Jesse C., Michael H. Thiazolidinediones as anti-cancer agents. Cancer Therapy 2008, 6(A):25-34.
5. Chunhua Q., Robert B., Roger S., et al. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Research 2003, 63:958-964.
6. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. Journal of Immunology 1988, 140:2197-2200.
7. Daniela B., Sabrina G., Saveria A., Hong Y.Q., Maria B. Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Research and Treatment 2009, 113:423-434.
8. Deborah L.K., Xiwei W., Yun Y., Gerd P.P. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Research 2009, 27:11-14.
9. Desmedt C., Haibe-Kains B., Wirapati P., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical Cancer Research 2008, 14:5158-5165.
10. Dinh P., Sotiriou C., Piccart M.J. The evolution of treatment strategies: aiming at the target. Breast 2007, 16:10-16.
11. Elisabetta M., Pasha S., Peter T., Ronald M.E., Katherine J.M. Terminal differentiation of human breast cancer through PPARγ. Molecular Cell 1998, 1:465-470.
12. EmadA R., MaysaE E., AndrewR G., AndrewH S.L., JohnF R. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
13. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Human Molecular Genetics 2007, 16(Spec No1):R50-R59.
14. Fenner M.H., Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opinion on Investigational Drugs 2005, 14:557-568.
15. Gert S., Karen D., Hans W., Philippe M., Robert P. Triple-negative breast cancer. Current Opinion in Oncology 2008, 20:614-620.
16. Gloria J.M., Sashi N., Allan K.T., Fran G., Yi H.X. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results Database. Cancer 2007, 110:876-884.
17. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 2003, 349:2042-2054.
18. Horsman M.R., Nordsmark M., Hoyer M., Overgaard J. Direct evidence that hydralazine can induce hypoxia in both trans-planted and spontaneous murine tumors. British Journal of Cancer 1995, 72:1474-1478.
19. Jarrar M.H., Baranova A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. Journal of Cellular and Molecular Medicine 2007, 11:71-87.
20. Jones C., Nonni A.V., Fulford L., et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. British Journal of Cancer 2001, 85:422-427.
21. Judith H., John H., Maggie C.C., Torsten O.N., Charles M.P. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. Journal of Clinical Oncology 2009, 27:1168-1176.
22. Lu J., Imamura K., Nomura S., Mafune K., Nakajima A., Kadowaki T., Kubota N., Terauchi Y., Ishii G., Ochiai A., Esumi H., Kaminishi M. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Research 2005, 65:4769-4774.
23. Lu M., Kwan T., Yu C., Chen F., Freedman B., Schafer J.M., Lee E.J., Jameson J.L., Jordan V.C., Cryns V.L. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. Journal of Biological Chemistry 2005, 280:6742-6751.
24. Mangelsdorf D.J., Thummel, Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
25. Noga B.Q., Jun Y., Eric L.S., Michail S., Lauren L.C. Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(37):14076-14081.
26. Nunez N.P., Liu H., Meadows G.G. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, breast cancer cells. Cancer Letters 2006, 236:133-141.
27. Nwankwo J.O., Robbins M.E. Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2001, 64:241-245.
28. Perlmann T., Evans R.M. Nuclear receptors in Sicily: all in the famiglia. Cell 1997, 90:391-397.
29. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research 2005, 11:5678-5685.
30. Sato H., Ishihara S., Kawashima K., Moriyama N., Suetsugu H., Kazumori H., Okuyama T., Rumi M.A., Fukuda R., Nagasue N., Kinoshita Y. Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. British Journal of Cancer 2000, 83:1394-1400.
31. Suh N., Wang Y., Williams C.R., Risingsong R., Gilmer T., Willson T.M., Sporn M.B. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Research 1999, 59:5671-5673.
32. Takashima T., Fujiwara Y., Higuchi K., Arakawa T., Yano Y., Hasuma T., Otani S. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. International Journal of Oncology 2001, 19:465-471.
33. WenG J., Anthony D.J., Robert E. Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPAR co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. International Journal of Cancer 2003, 106:752-757.
34. Yamagata M., Tannock I.F. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. British Journal of Cancer 1996, 73:1324-1328.